LLY - Eli Lilly and Company
113.02 -0.33 (-0.29%)
After hours: 4:06PM EDT
| Previous Close | 113.59 |
| Open | 113.93 |
| Bid | 113.23 x 900 |
| Ask | 113.23 x 1200 |
| Day's Range | 112.41 - 114.24 |
| 52 Week Range | 73.69 - 116.61 |
| Volume | 2,883,888 |
| Avg. Volume | 4,138,560 |
| Market Cap | 113.067B |
| Beta (3Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | Oct 23, 2018 |
| Forward Dividend & Yield | 2.25 (2.04%) |
| Ex-Dividend Date | 2018-08-14 |
| 1y Target Est | 111.63 |
- Market Realist•3 hours ago
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segment—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
- Motley Fool•4 hours ago
Better Buy: GlaxoSmithKline plc vs. Eli Lilly
Which stock is a better bet in an uncertain market?
Markit•8 hours agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Reuters•yesterday
Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
Reuters•yesterdayExpress Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
- Investing.com•yesterday
Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
Investing.com - Stocks in focus in pre-market trade Wednesday:
- Investopedia•yesterday
5 Blue Chip Drug Stocks Poised for Long-Term Gains
Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.
- Reuters•2 days ago
Minnesota accuses insulin makers of deceptive drug pricing
Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively raising prices for insulin. In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002.
- Zacks•2 days ago
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
Market Realist•2 days agoHow Nektar Therapeutics Is Positioned In October
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
- PR Newswire•2 days ago
Karen Walker Elected to Lilly Board of Directors
INDIANAPOLIS, Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee. Walker is the Senior Vice President and Chief Marketing Officer at Cisco where she has worked since 2009.
- Market Realist•3 days ago
What’s Expected for Merck’s Q3 2018 Earnings
Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.
- PR Newswire•3 days ago
Lilly Declares Fourth-Quarter 2018 Dividend
INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common ...
InvestorPlace•3 days ago3 Healthcare Stocks to Buy Amid the Carnage
My weekend scanning revealed relative strength emanating from healthcare stocks. For the brave souls who want to continue playing, I suggest looking for relative strength to buy. Here are three healthcare stocks to buy.
Bloomberg•3 days agoEli Lilly’s IPO of Animal Health Company Is Getting ‘Ahead of Itself,’ Goldman Says
While no analyst tracked by Bloomberg has yet rated Elanco a sell, the drugmaker for animals earned eight hold ratings, more than the five buys it received. While the company may benefit from a macro environment that includes increasing meat consumption and “humanization of pets,” Goldman Sachs analyst Jami Rubin said “the stock has gotten ahead of itself” after shares surged 36 percent through last week since a September listing at $24 per share. With the average analyst price target at $34.60, implying a return of less than 9 percent over the next twelve months, Elanco may be coming up short as investors draw comparisons to Zoetis Inc. Zoetis, the top company in medicines for pets and cattle, has seen its shares more than triple since their debut in 2013.
- CNBC•3 days ago
Drugmakers will soon talk about price in ads — but not as explicitly as Trump administration wants
Some drugmakers will soon tell consumers where they can see information about drug prices. Health and Human Services Secretary Alex Azar is expected on Monday to introduce a proposal that would require drugmakers to include the list price in their direct-to-consumer advertisements. This is a key piece of President Donald Trump's blueprint to lower drug prices.
- Market Realist•3 days ago
Novartis’ Estimates and Recommendations on October 12
Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).
- Market Realist•3 days ago
Novartis: What to Expect from Q3 Earnings on October 18
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
- PR Newswire•3 days ago
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
- Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus ...
Market Realist•6 days agoA Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
Market Realist•6 days agoHow Analysts View Bausch Health in October
In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.
- Zacks•6 days ago
3 Large-Cap Pharma Stocks Performing Better Than Industry
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
- Zacks•6 days ago
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
Is (LLY) Outperforming Other Medical Stocks This Year?
- Zacks•6 days ago
This is Why Eli Lilly (LLY) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
- PR Newswire•6 days ago
Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC
- National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with many ...
